{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T09:29:47Z","timestamp":1782638987839,"version":"3.54.5"},"reference-count":188,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To evaluate efficacy and safety of iguratimod (IGU) in the treatment of rheumatic and autoimmune diseases.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Databases such as Pubmed, Embase, Sinomed were searched (as of July 2022) to collect randomized controlled trials (RCTs) of IGU in the treatment of rheumatic and autoimmune diseases. Two researchers independently screened the literature, extracted data, assessed the risk of bias of the included literature, and performed meta-analysis using RevMan 5.4 software.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 84 RCTs and 4 types of rheumatic and autoimmune diseases [rheumatoid arthritis (RA), ankylosing spondylitis (AS), primary Sj\u00f6gren\u2019s syndrome (PSS) and Autoimmune disease with interstitial pneumonia]. Forty-three RCTs reported RA and showed that IGU + MTX therapy can improve ACR20 (RR 1.45 [1.14, 1.84], <jats:italic>p<\/jats:italic> = 0.003), ACR50 (RR 1.80 [1.43, 2.26], <jats:italic>p<\/jats:italic> &amp;lt; 0.0000), ACR70 (RR 1.84 [1.27, 2.67], <jats:italic>p<\/jats:italic> = 0.001), DAS28 (WMD \u22121.11 [\u22121.69, \u22120.52], <jats:italic>p<\/jats:italic> = 0.0002), reduce ESR (WMD \u221211.05 [\u221214.58, \u22127.51], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), CRP (SMD \u22121.52 [\u22122.02, \u22121.02], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), RF (SMD \u22121.65 [\u22122.48, \u22120.82], <jats:italic>p<\/jats:italic> &amp;lt; 0.0001), and have a lower incidence of adverse events (RR 0.84 [0.78, 0.91], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001) than the control group. Nine RCTs reported AS and showed that IGU can decrease the BASDAI score (SMD \u22121.62 [\u22122.20, \u22121.05], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), BASFI score (WMD \u22121.07 [\u22121.39, \u22120.75], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), VAS (WMD \u22122.01 [\u22122.83, \u22121.19], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), inflammation levels (decreasing ESR, CRP and TNF-\u03b1). Thirty-two RCTs reported PSS and showed that IGU can reduce the ESSPRI score (IGU + other therapy group: WMD \u22121.71 [\u22122.44, \u22120.98], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001; IGU only group: WMD \u22122.10 [\u22122.40, \u22121.81], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001) and ESSDAI score (IGU + other therapy group: WMD \u22121.62 [\u22122.30, \u22120.94], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001; IGU only group: WMD \u22121.51 [\u22121.65, \u22121.37], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), inhibit the inflammation factors (reduce ESR, CRP and RF) and increase Schirmer\u2019s test score (IGU + other therapy group: WMD 2.18 [1.76, 2.59], <jats:italic>p<\/jats:italic> &amp;lt; 0.00001; IGU only group: WMD 1.55 [0.35, 2.75], <jats:italic>p<\/jats:italic> = 0.01); The incidence of adverse events in IGU group was also lower than that in control group (IGU only group: RR 0.66 [0.48, 0.98], <jats:italic>p<\/jats:italic> = 0.01). Three RCTs reported Autoimmune disease with interstitial pneumonia and showed that IGU may improve lung function.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Based on current evidence, IGU may be a safe and effective therapy for RA, AS, PSS and autoimmune diseases with interstitial pneumonia.<\/jats:p><jats:p><jats:bold>Systematic Review Registration<\/jats:bold>: (CRD42021289489).<\/jats:p>","DOI":"10.3389\/fphar.2023.1189142","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:32:26Z","timestamp":1701959546000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Liuting","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-021-00603-4","article-title":"Rheumatic diseases in africa","volume":"17","author":"Adelowo","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cca.2020.11.003","article-title":"Traditional and modern management strategies for rheumatoid arthritis","volume":"512","author":"Akram","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102405","DOI":"10.1016\/j.jaut.2020.102405","article-title":"Precision medicine and management of rheumatoid arthritis","volume":"110","author":"Aletaha","year":"2020","journal-title":"J. Autoimmun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Lupus nephritis. Nat. Rev. Dis. Prim."},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41581-020-00388-x","article-title":"Advances in ANCA-associated vasculitis and lupus nephritis","volume":"17","author":"Ayoub","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B7","first-page":"1724","article-title":"Observation on the clinical effect of Iramod in the treatment of primary Sjogren\u2019s syndrome","volume":"48","author":"Bai","year":"2019","journal-title":"Shanxi Med. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3969\/j.issn.1674-4985.2021.02.011","article-title":"Observation on the clinical effect of iguratimod in the treatment of axial spondyloarthritis","volume":"18","author":"Bai","year":"2021","journal-title":"Chin. Med. Innov."},{"key":"B9","volume-title":"The effect of Iguratimod combined with methotrexate on serum VEGF levels in patients with rheumatoid arthritis and evaluation of the efficacy[D]","author":"Bi","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","article-title":"B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies","volume":"47","author":"Canny","year":"2021","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/ard.2006.057133","article-title":"Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study","volume":"66","author":"Capell","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res. Hob."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.3390\/ijms221910659","article-title":"Vitamin D and rheumatic diseases: a review of clinical evidence","volume":"22","author":"Charoenngam","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/polym10050552","article-title":"Enhanced poly(propylene carbonate) with thermoplastic networks: a one-pot synthesis from carbon dioxide, propylene oxide, and a carboxylic dianhydride","volume":"28","author":"Chen","year":"2018","journal-title":"Zhejiang J. Integr. Traditional Chin. West. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00393-020-00944-7","article-title":"Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"80","author":"Chen","year":"2021","journal-title":"Z Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.19381\/j.issn.1001-7585.2022.02.025","article-title":"Analysis of curative effect of iguratimod in the treatment of elderly patients with pSS and its effect on B cell activity and secretion level of immunoglobulin G","volume":"35","author":"Chen","year":"2022","journal-title":"Med. Theory Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-0039-1684007","article-title":"Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease","volume":"40","author":"Chernau","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10067-020-05320-z","article-title":"Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management","volume":"40","author":"Dai","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B20","first-page":"114","article-title":"Observation on the therapeutic effect of methotrexate combined with Ailamod in the treatment of rheumatoid arthritis","volume":"34","author":"Dai","year":"2022","journal-title":"Mod. Pract. Med."},{"key":"B21","article-title":"Chapter 8: assessing risk of bias in included studies","volume-title":"Cochrane handbook or systematic reviews of interventions version 6.1.0","author":"Deeks","year":""},{"key":"B22","article-title":"Chapter 9: analyzing data and undertaking meta-analyses","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":""},{"key":"B23","article-title":"Chapter 16: special topics in statistics","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":""},{"key":"B24","volume-title":"The effect of Iguratimod on the proliferation and migration of fibroblast-like synovial cells in rheumatoid arthritis and the clinical observation[D]","author":"Deng","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5684293","DOI":"10.1155\/2022\/5684293","article-title":"Influence of iguratimod on bone metabolism in patients with rheumatoid arthritis: a meta-analysis","volume":"2022","author":"Deng","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.19347\/j.cnki.2096-1413.202217020","article-title":"The effect of Ailamod in the treatment of senile primary Sj\u00f6gren's syndrome and its influence on the SSDAI and ESSPRI scores of patients","volume":"7","author":"Ding","year":"2022","journal-title":"Clin. Med. Res. Pract."},{"key":"B94","doi-asserted-by":"publisher","first-page":"45","DOI":"10.16190\/j.cnki.45-1211\/r.2019.01.011","article-title":"Efficacy of Tripterygium wilfordii polyglycosides combined with iguratimod in the treatment of RA complicated with interstitial lung disease and its effect on serum HIF-1\u03b1 and IL-22 levels","volume":"36","author":"Dong","year":"2019","journal-title":"J. Guangxi Med. Univ."},{"key":"B139","first-page":"146","article-title":"Efficacy and safety of iguratimod and hydroxychloroquine in the treatment of Sj\u00f6gren'ssyndrome","volume":"11","author":"Donghui","year":"2019","journal-title":"DOCTOR"},{"key":"B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11926-020-00921-8","article-title":"Therapeutic options and cost-effectiveness for rheumatoid arthritis treatment","volume":"22","author":"Drosos","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar2554","article-title":"T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis","volume":"10","author":"Du","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/annrheumdis-2021-eular.1486","article-title":"POS0664\u2005A multicenter randomized study in rheumatoid arthritis to compare iguratimod, methotrexate, or combination: 52 week efficacy and safety results of the smile trial","volume":"80","author":"Du","year":"","journal-title":"Rheum. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"684999","DOI":"10.3389\/fimmu.2021.684999","article-title":"The multiple roles of B cells in the pathogenesis of Sj\u00f6gren's syndrome","volume":"12","author":"Du","year":"","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","article-title":"Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial","volume":"34","author":"Duan","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/BOR.0000000000000703","article-title":"Management issues in rheumatoid arthritis-associated interstitial lung disease","volume":"32","author":"England","year":"2020","journal-title":"CurrOpinRheumatol"},{"key":"B33","first-page":"81","article-title":"The clinical efficacy of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"13","author":"Fan","year":"2020","journal-title":"J. Clin. Ration. Use"},{"key":"B34","first-page":"315","article-title":"Pathogenesis of primary Sj\u00f6gren's syndrome beyond B lymphocytes","volume":"38","author":"Fasano","year":"","journal-title":"Clin. Exp. Rheumatol."},{"key":"B35","first-page":"315","article-title":"Pathogenesis of primary Sj\u00f6gren's syndrome beyond B lymphocytes","volume":"38","author":"Fasano","year":"","journal-title":"Clin. Exp. Rheumatol."},{"key":"B172","first-page":"721","article-title":"Iramod inhibits transforming growth factor \u03b2_1-mediated activation and collagen secretion of human lung fibroblasts via Smad3\/p300 pathway","volume":"25","author":"Fu","year":"2021","journal-title":"Chin. J. Rheumatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","article-title":"Lupus nephritis: clinical presentations and outcomes in the 21st century","volume":"59","author":"Gasparotto","year":"2020","journal-title":"Rheumatol. Oxf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40273-020-00887-6","article-title":"Systematic literature review of economic evaluations of biological treatment sequences for patients with moderate to severe rheumatoid arthritis previously treated with disease-modifying anti-rheumatic drugs","volume":"38","author":"Ghabri","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.semarthrit.2015.01.008","article-title":"Rheumatoid arthritis: perioperative management of biologics and DMARDs","volume":"44","author":"Goodman","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"B39","volume-title":"GRADEpro guideline development tool [software]","author":"Gradepro","year":"2015"},{"key":"B40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1513\/AnnalsATS.201808-565CME","article-title":"Interstitial pneumonia with autoimmune features","volume":"16","author":"Graney","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B41","first-page":"158","article-title":"Clinical effect of methylprednisolone combined with iguratimod in the treatment of primary Sj\u00f6gren's syndrome and its influence on the level of immunoglobulin","volume":"28","author":"Gu","year":"2022","journal-title":"Contemp. Med."},{"key":"B42","first-page":"1","article-title":"Clinical effect of methylprednisolone combined with Ilamod in the treatment of elderly patients with primary Sjogren\u2019s syndrome","volume":"32","author":"Gu","year":"2020","journal-title":"Chin. Natl. Health Med."},{"key":"B43","first-page":"138","article-title":"The clinical efficacy of Ilamud combined with methotrexate in the treatment of early rheumatoid arthritis (RA)","volume":"26","author":"Gu","year":"2020","journal-title":"Contemp. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.13748\/j.cnki.issn1007-7693.2014.10.029","article-title":"Observation on the short-term clinical effect of Ilamod on rheumatoid arthritis complicated with chronic interstitial pneumonia","volume":"31","author":"Guifeng","year":"2014","journal-title":"China Mod. Appl. Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10165-006-0542-y","article-title":"Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study","volume":"17","author":"Hara","year":"2007","journal-title":"Mod. Rheumatol. Jpn. Rheum. Assoc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hara","year":"2014","journal-title":"Mod. Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"700982","DOI":"10.3389\/fmed.2021.700982","article-title":"Immunopathophysiology of juvenile spondyloarthritis (jSpA): the \"out of the box\" view on epigenetics, neuroendocrine pathways and role of the macrophage migration inhibitory factor (MIF)","volume":"8","author":"Harjacek","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B48","first-page":"152","article-title":"Clinical observation of Ilamod in the treatment of rheumatoid arthritis complicated with interstitial lung disease","volume":"19","author":"He","year":"2015","journal-title":"J. Pract. Clin. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13018-021-02603-2","article-title":"Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs","volume":"16","author":"Hu","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"B50","volume-title":"Efficacy and safety observation of Ellamod in the treatment of rheumatoid arthritis[D]","author":"Hu","year":"2014"},{"key":"B51","first-page":"92","article-title":"Observation on the short-term curative effect of Iramod in the treatment of ankylosing spondylitis","volume":"34","author":"Huang","year":"2018","journal-title":"Chin. Community Physician"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1093\/rheumatology\/keab364","article-title":"Mortality in patients with primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"60","author":"Huang","year":"2021","journal-title":"Rheumatol. Oxf."},{"key":"B53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41584-020-00562-2","article-title":"Rheumatic disease and COVID-19: epidemiology and outcomes","volume":"17","author":"Hyrich","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10165-005-0420-z","article-title":"Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study","volume":"15","author":"Ichikawa","year":"2005","journal-title":"Mod. Rheumatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10165-012-0724-8","article-title":"Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"B56","first-page":"106","article-title":"Analysis of the effect of iguratimod combined with hydroxychloroquine in the treatment of Sj\u00f6gren'ssyndrome","volume":"36","author":"Jia","year":"2020","journal-title":"Gansu Sci. Technol."},{"key":"B57","first-page":"90","article-title":"Observation on the clinical effect of Iramod combined treatment of primary Sjogren\u2019s syndrome","volume":"29","author":"Jiang","year":"2016","journal-title":"Clin. Misdiagnosis Mistreatment"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.27138\/d.cnki.ghuzc.2021.000018","article-title":"Clinical observation of Shure Cunjin granules combined with iguratimod in the treatment of primary Sj\u00f6gren's syndrome with high IgG[D]","author":"Jiang","year":"2021","journal-title":"Hunan Univ. Traditional Chin. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s10792-020-01490-6","article-title":"The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren's syndrome patients","volume":"40","author":"Jiang","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"B60","first-page":"719","article-title":"Observation on the curative effect of Iramod in the treatment of primary Sjogren\u2019s syndrome","volume":"26","author":"Jiang","year":"2014","journal-title":"West. Med."},{"key":"B61","first-page":"106","article-title":"Evaluation of the clinical efficacy of methotrexate and ilamod in the treatment of refractory rheumatoid arthritis","volume":"58","author":"Ju","year":"2020","journal-title":"China Mod. Dr."},{"key":"B62","doi-asserted-by":"publisher","first-page":"210011","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13075-020-02154-7","article-title":"Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study","volume":"22","author":"Kang","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"101473","DOI":"10.1016\/j.berh.2019.101473","article-title":"The microbiome in autoimmune rheumatic disease","volume":"34","author":"Konig","year":"2020","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","article-title":"Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Kremer","year":"2002","journal-title":"Ann. Intern Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15887\/j.cnki.13-1389\/r.2020.21.004","article-title":"Clinical efficacy of islamod in the treatment of inflammatory myopathy complicated with interstitial pneumonia","volume":"13","author":"Man","year":"2020","journal-title":"J. Clin. Ration. Med."},{"key":"B67","first-page":"35","article-title":"Efficacy of methylprednisolone combined with ilamod in the treatment of primary Sjogren\u2019s syndrome and its effect on immunoglobulin levels","volume":"27","author":"Li","year":"2018","journal-title":"China Pharm."},{"key":"B68","first-page":"2981","article-title":"The effect of irammod combined with methotrexate in the treatment of rheumatoid arthritis with peripheral blood nuclear factor kappa B receptor activator ligand and bone protective factor","volume":"20","author":"Li","year":"2020","journal-title":"Chin. Med. Clin."},{"key":"B69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41413-019-0067-6","article-title":"Iguratimod: a valuable remedy from the Asia pacific region for ameliorating autoimmune diseases and protecting bone physiology","volume":"7","author":"Li","year":"","journal-title":"Bone Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2016.03.003","article-title":"Retraction notice to \"\u00df-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome\": lung 86\/2 (2014) 144-150","volume":"45","author":"Li","year":"2016","journal-title":"Shaanxi Med. J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"310628","DOI":"10.1155\/2013\/310628","article-title":"Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis","volume":"2013","author":"Li","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1109\/TCBB.2018.2846253","article-title":"An integrated reconciliation framework for domain, gene, and species level evolution","volume":"28","author":"Li","year":"","journal-title":"China Pharm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fnins.2020.00189","article-title":"Memory traces diminished by exercise affect new learning as proactive facilitation","volume":"6","author":"Li","year":"2020","journal-title":"World Complex Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s11010-021-04142-0","article-title":"LncRNA TUG1 exhibits pro-fibrosis activity in hypertrophic scar through TAK1\/YAP\/TAZ pathway via miR-27b-3p","volume":"34","author":"Li","year":"","journal-title":"J Med Theor Prac"},{"key":"B75","doi-asserted-by":"publisher","first-page":"678864","DOI":"10.3389\/fmed.2021.678864","article-title":"Randomised, double-blind, placebo-controlled study of iguratimod in the treatment of active spondyloarthritis","volume":"8","author":"Li","year":"","journal-title":"Front. Med. (Lausanne)."},{"key":"B76","first-page":"32","article-title":"Effects of iguratimod on the levels of ESR, CRP and immunoglobulin in patients with primary Sj\u00f6gren'ssyndrome","volume":"42","author":"Liang","year":"2021","journal-title":"Shanghai Med."},{"key":"B77","first-page":"124","article-title":"A clinical study on the treatment of rheumatoid arthritis complicated with pulmonary interstitium by iguratimod","volume":"13","author":"Lin","year":"2016","journal-title":"North. Pharm."},{"key":"B78","first-page":"9","article-title":"Preliminary observation on the treatment of ankylosing spondylitis with Iramod","volume":"12","author":"Lin","year":"2019","journal-title":"J. Clin. Ration. Use"},{"key":"B79","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12906-021-03252-y","article-title":"Clinical safety of total glucosides of paeony adjuvant therapy for rheumatoid arthritis treatment: a systematic review and meta-analysis","volume":"21","author":"Liu","year":"","journal-title":"BMC Complement. Med. Ther."},{"key":"B80","first-page":"57","article-title":"Observation on the effect of Ailamod in the treatment of Sj\u00f6gren's syndrome","volume":"38","author":"Liu","year":"2022","journal-title":"Chin. Community Physician"},{"key":"B81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10067-020-05207-z","article-title":"Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis","volume":"40","author":"Liu","year":"","journal-title":"Clin. Rheumatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.12998\/wjcc.v9.i10.2181","article-title":"Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-\u03baB pathway","volume":"9","author":"Liu","year":"","journal-title":"World J. Clin. Cases"},{"key":"B83","doi-asserted-by":"publisher","first-page":"993860","DOI":"10.3389\/fimmu.2023.993860","article-title":"Efficacy and safety of iguratimod in the treatment of ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Long","year":"2023","journal-title":"Front. Immunol."},{"key":"B84","volume-title":"The therapeutic effect of combined application of iguratimod and methotrexate on active rheumatoid arthritis[D]","author":"Lu","year":"2014"},{"key":"B85","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B86","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial","volume":"121","author":"L\u00fc","year":"2008","journal-title":"Chin. Med. J. Engl."},{"key":"B87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.15887\/j.cnki.13-1389\/r.2021.31.018","article-title":"Clinical efficacy of iguratimod combined with hydroxychloroquine sulfate in the treatment of primary Sj\u00f6gren'ssyndrome","volume":"14","author":"Lu","year":"2021","journal-title":"J. Clin. Ration. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.13507\/j.issn.1674-3474.2019.12.024","article-title":"Clinical analysis of 46 cases of PrimarySjogren\u2019s syndrome treated by ilamud","volume":"33","author":"Luo","year":"2019","journal-title":"Chin. J. Pract. Diagn. Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","article-title":"A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide","volume":"191","author":"Luo","year":"2013","journal-title":"J. Immunol."},{"key":"B90","first-page":"323","article-title":"Study on the immunological mechanism of Ilarmod in improving idiopathic pulmonary fibrosis in mice","volume":"2015","author":"Luo","year":"2015","journal-title":"Proc. 10th Natl. Congr. Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.foodchem.2018.06.042","article-title":"Revisiting the enzymatic kinetics of pepsin using isothermal titration calorimetry","volume":"10","author":"Luo","year":"","journal-title":"Clin. Res. Traditional Chin. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/03009742.2017.1390150","article-title":"Is iguratimod effective in refractory axial spondyloarthritis?","volume":"47","author":"Luo","year":"","journal-title":"Scand. J. Rheumatol."},{"key":"B93","first-page":"291","article-title":"Interstitial lung disease in Sj\u00f6gren's syndrome: a clinical review","volume":"38","author":"Luppi","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.3390\/ijms20236021","article-title":"Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Ma","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan","year":"2020","journal-title":"Lupus"},{"key":"B98","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4140\/TCP.n.2018.691","article-title":"Management of primary Sj\u00f6gren's syndrome","volume":"33","author":"Marshall","year":"2018","journal-title":"Consult Pharm."},{"key":"B99","first-page":"137","article-title":"The effect of methotrexate combined with Ilamud in the treatment of refractory rheumatoid arthritis","volume":"13","author":"Meng","year":"","journal-title":"China Med. Her."},{"key":"B100","first-page":"148","article-title":"Iguratimod combined with methotrexate on angiogenesis-related cytokines in patients with refractory rheumatoid arthritis the influence of","volume":"35","author":"Meng","year":"","journal-title":"Med. Her."},{"key":"B101","first-page":"40","article-title":"Short-term clinical efficacy of methotrexate combined with Iguratimod on refractory rheumatoid arthritis","volume":"28","author":"Meng","year":"2015","journal-title":"Chin. J. Clin. Res."},{"key":"B102","first-page":"1098","article-title":"Clinical study on the treatment of senile rheumatoid arthritis with Iguratimod tablets combined with methotrexate tablets","volume":"33","author":"Meng","year":"2017","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10067-020-05208-y","article-title":"Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis","volume":"40","author":"Mizutani","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B104","first-page":"156","article-title":"Clinical study on the treatment of active rheumatoid arthritis with Iguratimod combined with methotrexate","volume":"10","author":"Mo","year":"2015","journal-title":"Intern. Med."},{"key":"B105","first-page":"40","article-title":"A randomized controlled trial of methotrexate combined with Iguratimod in the treatment of active rheumatoid arthritis","volume":"52","author":"Mo","year":"2018","journal-title":"J. Fujian Med. Univ."},{"key":"B106","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.lanwpc.2021.100128","article-title":"Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: a nationwide, prospective real-world study","volume":"10","author":"Mu","year":"2021","journal-title":"Lancet Reg. Health West Pac"},{"key":"B107","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/life11050457","article-title":"Iguratimod: novel molecular insights and a new csDMARD for rheumatoid arthritis, from Japan to the world","volume":"11","author":"Nozaki","year":"2021","journal-title":"Life (Basel)"},{"key":"B108","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/14397595.2014.998361","article-title":"Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis","volume":"25","author":"Okamura","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.berh.2019.101477","article-title":"The epidemiology of established rheumatoid arthritis","volume":"33","author":"Ot\u00f3n","year":"2019","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"911810","DOI":"10.3389\/fphar.2022.911810","article-title":"Effectiveness and safety of iguratimod monotherapy or combined with methotrexate in treating rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Ouyang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B112","first-page":"118","article-title":"Efficacy of Iramud combined with Etanercept in the treatment of ankylosing spondylitis","volume":"20","author":"Pang","year":"2020","journal-title":"J. Trop. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"621208","DOI":"10.3389\/fphar.2021.621208","article-title":"Effectiveness and safety of iguratimod in treating primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"12","author":"Pu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B114","first-page":"217","article-title":"Study on the efficacy and safety of methotrexate and isilamod in the treatment of rheumatoid arthritis","volume":"36","author":"Qi","year":"2019","journal-title":"Chin. J. Drug Eval."},{"key":"B115","first-page":"235","article-title":"Observation on the clinical effect of Iramod in the treatment of refractory ankylosing spondylitis","volume":"26","author":"Qiu","year":"2016","journal-title":"J. Jiangsu Univ. Med. Ed."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Radu","year":"2021","journal-title":"Cells"},{"key":"B117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15912\/j.cnki.gocm.2014.29.027","article-title":"Observation on the clinical efficacy of Ailamod in the treatment of rheumatoid arthritis","volume":"12","author":"Rao","year":"2014","journal-title":"Chin. Med. Guide"},{"key":"B118","doi-asserted-by":"publisher","first-page":"152","DOI":"10.16050\/j.cnki.issn1674-6309.2022.02.008","article-title":"Efficacy of iguratimod in the treatment of Sj\u00f6gren's syndrome patients and its influence on immune function","volume":"44","author":"Rao","year":"2022","journal-title":"J. Ningxia Med. Univ."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sj\u00f6gren's syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Rivi\u00e8re","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B120","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4997\/JRCPE.2020.307","article-title":"Interstitial pneumonia with autoimmune features","volume":"50","author":"Santhanam","year":"2020","journal-title":"J. R. Coll. Physicians Edinb"},{"key":"B121","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations","author":"Sch\u00fcnemann","year":"2013"},{"key":"B122","first-page":"1561","article-title":"Efficacy and safety analysis of Ailamod in the treatment of rheumatoid arthritis","volume":"21","author":"Shang","year":"2014","journal-title":"Clin. Med. Eng."},{"key":"B123","first-page":"593","article-title":"Efficacy of Ailamod tablet monotherapy in the treatment of active rheumatoid arthritis and its effect on bone metabolism","volume":"54","author":"Shang","year":"2019","journal-title":"Jiangxi Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren's syndrome: a randomized, placebo-controlled clinical trial","volume":"29","author":"Shao","year":"2020","journal-title":"Scand. J. Rheumatol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"107936","DOI":"10.1016\/j.intimp.2021.107936","article-title":"Iguratimod decreases bleomycin-induced pulmonary fibrosis in association with inhibition of TNF-\u03b1 in mice","volume":"99","author":"Shao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B126","first-page":"33","article-title":"Efficacy and safety of methotrexate combined with iguratimod in the treatment of active rheumatoid arthritis","volume":"55","author":"Shi","year":"2015","journal-title":"J. Nanchang Univ. Med. Ed."},{"key":"B127","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1007\/s10067-021-05746-z","article-title":"Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"40","author":"Shrestha","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s10067-020-04986-9","article-title":"Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"39","author":"Shrestha","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch. Intern Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3969\/j.issn.1674-4659.2022.01.0041","article-title":"Clinical efficacy of islamod combined with methotrexate in the treatment of rheumatoid arthritis and its effect on bone metabolism in patients","volume":"29","author":"Sun","year":"2022","journal-title":"Clin. Med. Eng."},{"key":"B131","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14397595.2018.1510879","article-title":"The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis","volume":"29","author":"Suto","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","article-title":"Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice","volume":"42","author":"Tanaka","year":"2003","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B133","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.lanwpc.2021.100144","article-title":"Conflict between efficacy and economy in rheumatoid arthritis treatment: iguratimod is found at a compromise","volume":"10","author":"Tanaka","year":"2021","journal-title":"Lancet Reg. Health West Pac"},{"key":"B134","doi-asserted-by":"publisher","first-page":"ii15","DOI":"10.1093\/rheumatology\/kew352","article-title":"Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis","volume":"55","author":"Tanaka","year":"2016","journal-title":"Rheumatol. Oxf."},{"key":"B135","first-page":"391","article-title":"The effect of Iguratimod combined with methotrexate on serum M-CSF, IL-6, IL-8 and bone metabolism in patients with rheumatoid arthritis","volume":"28","author":"Tian","year":"2017","journal-title":"Hainan Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3760\/cma.j.issn.1007-7480.2020.03.002","article-title":"Efficacy and safety of ellamod or leflunomide combined with methotrexate in the treatment of active rheumatoid arthritis sexual comparison: a multicenter randomized double-blind double-simulation controlled clinical study","volume":"24","author":"Tian","year":"2020","journal-title":"Chin. J. Rheumatology"},{"key":"B137","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis","volume":"32","author":"van der Woude","year":"2018","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B138","first-page":"301","article-title":"Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sj\u00f6gren's syndrome","volume":"38","author":"Vehof","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"B140","first-page":"231","article-title":"Clinical study on the treatment of rheumatoid arthritis with methotrexate tablets combined with Iguratimod tablets","volume":"35","author":"Wang","year":"","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10067-017-3668-8","article-title":"Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis","volume":"36","author":"Wang","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"75","DOI":"10.16462\/j.cnki.zhjbkz.2018.01.017","article-title":"Clinical study ofEffectiveness and safety of iguratimod in treating primary Sjogren\u2019sSyndrome","volume":"22","author":"Wang","year":"","journal-title":"Chin. J. Dis. Control Prev."},{"key":"B144","volume-title":"Study on the effect of iguratimod on bone metabolism in patients with rheumatoid arthritis[D]","author":"Wang","year":"2017"},{"key":"B145","first-page":"2055","article-title":"Evaluation of the efficacy of high-frequency ultrasound in the treatment of rheumatoid arthritis","volume":"28","author":"Wang","year":"2022","journal-title":"Med. Rev."},{"key":"B146","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1573405614666180131163321","article-title":"Comparison of mammography and ultrasonography for tumor size of DCIS of breast cancer","volume":"25","author":"Wang","year":"","journal-title":"Geriatrics Health Care"},{"key":"B147","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial lung disease in connective tissue disease-mechanisms and management","volume":"10","author":"Wells","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"B149","first-page":"183","article-title":"Repair effect and safety of Ellamod combined with methotrexate and tripterygium wilfordii on articular cartilage cell damage in rheumatoid arthritis Analysis","volume":"26","author":"Wu","year":"2022","journal-title":"Anhui Med."},{"key":"B150","first-page":"76","article-title":"Observation on the effects of Iguratimod and Tripterygium Glycosides in the treatment of rheumatoid arthritis","volume":"20","author":"Xia","year":"2020","journal-title":"Pract. Integr. Traditional Chin. West. Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00393-015-1641-y","article-title":"Iguratimod in combination with methotrexate in active rheumatoid arthritis: therapeutic effects","volume":"75","author":"Xia","year":"2016","journal-title":"Z Rheumatol."},{"key":"B152","first-page":"263","article-title":"Analysis of clinical effect of iguratimod combined treatment on primary Sj\u00f6gren'ssyndrome","volume":"27","author":"Xia","year":"2017","journal-title":"China Health Nutr."},{"key":"B153","first-page":"1358","article-title":"Hydroxychloroquine sulfate combined with total glucosides of paeony and ilamod in the treatment of primary Sjogren\u2019s syndrome","volume":"32","author":"Xie","year":"","journal-title":"West. Med."},{"key":"B154","first-page":"831","article-title":"The effect of Iguratimod combined with MTX on IL-1, serum TNF-\u03b1 and VEGF levels in patients with refractory rheumatoid arthritis","volume":"42","author":"Xie","year":"2018","journal-title":"Guizhou Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fphar.2020.00073","article-title":"Iguratimod as a new drug for rheumatoid arthritis: current landscape","volume":"11","author":"Xie","year":"","journal-title":"Front. Pharmacol."},{"key":"B156","first-page":"93","article-title":"The clinical efficacy of methotrexate combined with iguratimod on active rheumatoid arthritis","volume":"29","author":"Xiong","year":"2020","journal-title":"Henan Med. Res."},{"key":"B157","first-page":"915","article-title":"Study on the efficacy and safety of Iramod in the treatment of ankylosing spondylitis","volume":"50","author":"Xu","year":"2019","journal-title":"New Med."},{"key":"B158","first-page":"120","article-title":"Clinical study of methotrexate combined with Ilamud in the treatment of rheumatoid arthritis","volume":"19","author":"Xu","year":"","journal-title":"J. Clin. Med. Pract."},{"key":"B159","first-page":"915","article-title":"Comparison of the efficacy and safety of iguratimod and hydroxychloroquine in the treatment of patients with Sj\u00f6gren'ssyndrome","volume":"16","author":"Xu","year":"","journal-title":"J. Difficult Difficult Dis."},{"key":"B160","first-page":"47","article-title":"Clinical observation on the treatment of rheumatoid arthritis with Iguratimod combined with methotrexate","volume":"15","author":"Xu","year":"","journal-title":"Guide Chin. Med."},{"key":"B161","first-page":"833","article-title":"Study on the effect of iguratimod combined with methotrexate treatment on anti-cyclic guanidine peptide antibodies and other indicators in patients with rheumatoid arthritis","volume":"32","author":"Xu","year":"","journal-title":"J. Clin. Intern. Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"421","DOI":"10.19842\/j.cnki.issn.0253-9934.2021.06.013","article-title":"Observation on the clinical efficacy of iguratimod in the treatment of axial spondyloarthritis","volume":"44","author":"Xu","year":"2021","journal-title":"Shanghai Med. J."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e108273","DOI":"10.1371\/journal.pone.0108273","article-title":"Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL\/lpr mice","volume":"9","author":"Yan","year":"2014","journal-title":"PLoS One"},{"key":"B164","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1186\/s13063-021-05475-3","article-title":"Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study)","volume":"22","author":"Yan","year":"2021","journal-title":"Trials"},{"key":"B165","first-page":"369","article-title":"Effect of Iguratimod combined with methotrexate on serum-related cytokines and bone metabolism in patients with rheumatoid arthritis","volume":"34","author":"Yan","year":"2018","journal-title":"J. Changchun Univ. Traditional Chin. Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-019-1874-2","article-title":"Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis","volume":"21","author":"Ye","year":"","journal-title":"Arthritis Res. Ther."},{"key":"B167","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-019-1874-2","article-title":"Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis","volume":"21","author":"Ye","year":"","journal-title":"Arthritis Res. Ther."},{"key":"B95","first-page":"147+149","article-title":"Observation of the changes of ESR, CRP, IgG, IgA, IgM levels in patients with primary Sjogren\u2019s syndrome by Iramod","volume":"5","author":"Yi","year":"2018","journal-title":"Electron. J. Clin. Med. Literature"},{"key":"B168","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.ejro.2020.100311","article-title":"Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): evolving concept of CT findings, pathology and management","volume":"8","author":"Yoo","year":"2020","journal-title":"Eur. J. Radiol. Open"},{"key":"B169","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/14397595.2015.1069475","article-title":"Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod","volume":"26","author":"Yoshioka","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"B170","first-page":"150","article-title":"Clinical analysis of Iramod in the treatment of primary Sjogren\u2019s syndrome","volume":"18","author":"Yu","year":"2020","journal-title":"Guide Chin. Med."},{"key":"B171","first-page":"163","article-title":"Efficacy of islammod combined with methotrexate in the treatment of refractory ankylosing spondylitis and its effect on serum SOD and CTX-I levels in patients","volume":"29","author":"Yuan","year":"2020","journal-title":"J. Pharm. Epidemiol."},{"key":"B173","first-page":"118","article-title":"Observation on the efficacy of Iramod in the treatment of ankylosing spondylitis","volume":"27","author":"Zeng","year":"2016","journal-title":"Hainan Med."},{"key":"B174","doi-asserted-by":"publisher","first-page":"924730","DOI":"10.3389\/fimmu.2022.924730","article-title":"A systematic review and meta-analysis of 19 randomized controlled trials of iguratimod combined with other therapies for sjogren's syndrome","volume":"13","author":"Zeng","year":"","journal-title":"Front. Immunol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"780154","DOI":"10.3389\/fphar.2021.780154","article-title":"The effect and safety of iguratimod combined with methotrexate on rheumatoid arthritis: a systematic review and meta-analysis based on a randomized controlled trial","volume":"12","author":"Zeng","year":"","journal-title":"Front. Pharmacol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"502","DOI":"10.15975\/j.cnki.gsyy.2018.06.010","article-title":"Clinical observation of Ailamod in the treatment of active rheumatoid arthritis","volume":"37","author":"Zhang","year":"2018","journal-title":"Gansu Med."},{"key":"B177","first-page":"452","article-title":"Efficacy and mechanism of iguratimod in the treatment of Sj\u00f6gren'ssyndrome","volume":"48","author":"Zhang","year":"2019","journal-title":"Shaanxi Med. J."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14164\/j.cnki.cn11-5581\/r.2019.20.001","article-title":"Efficacy evaluation of iguratimod in the treatment of Sj\u00f6gren's syndrome complicated with interstitial pulmonary disease","volume":"13","author":"Zhang","year":"2019","journal-title":"China Mod. Med. Appl."},{"key":"B179","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15912\/j.cnki.gocm.2019.32.081","article-title":"Comparative observation of iguratimod and hydroxychloroquine in the treatment of patients with Sj\u00f6gren'ssyndrome","volume":"17","author":"Zhang","year":"2019","journal-title":"Chin. Med. Guide"},{"key":"B180","first-page":"44","article-title":"The clinical effect of Iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"3","author":"Zhao","year":"2018","journal-title":"Clin. Med. Res. Pract."},{"key":"B181","first-page":"3627","article-title":"Comparison of the efficacy and safety of iguratimod and hydroxychloroquine in the treatment of Sj\u00f6gren'ssyndrome","volume":"20","author":"Zhao","year":"2020","journal-title":"Chin. Med. Clin. Med."},{"key":"B182","first-page":"2353","article-title":"Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate","volume":"28","author":"Zhao","year":"","journal-title":"Biomed. Res."},{"key":"B183","first-page":"35","article-title":"Observation on the effect of methylprednisolone combined with Iramud in the treatment of primary Sjogren\u2019s syndrome","volume":"31","author":"Zhao","year":"2019","journal-title":"Chin. Natl. Health Med."},{"key":"B184","first-page":"370","article-title":"The effect of iguratimod on the mouse model of bleomycin-induced pulmonary interstitial fibrosis","volume":"21","author":"Zhao","year":"","journal-title":"Chin. J. Rheumatology"},{"key":"B185","first-page":"450","article-title":"Clinical study of Iguratimod in the treatment of active rheumatoid arthritis","volume":"39","author":"Zhao","year":"2016","journal-title":"Chin. J. Postgraduates Med."},{"key":"B186","first-page":"93","article-title":"A study on the clinical efficacy of Ailamod on rheumatoid arthritis and the regulation of T helper cell subsets","volume":"20","author":"Zhu","year":"2016","journal-title":"Chin. Rheumatism J. Sci."},{"key":"B187","first-page":"104","article-title":"Efficacy observation of Ailamod in the treatment of Sj\u00f6gren's syndrome complicated with interstitial pneumonia","volume":"19","author":"Zhuang","year":"2021","journal-title":"Chin. Prescr. Med."},{"key":"B188","first-page":"100","article-title":"To explore the effect of iguratimod in the treatment of primary Sj\u00f6gren'ssyndrome","volume":"31","author":"Zhuang","year":"2020","journal-title":"Spec. Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1189142\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T14:33:40Z","timestamp":1701959620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1189142\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":188,"alternative-id":["10.3389\/fphar.2023.1189142"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1189142","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"article-number":"1189142"}}